Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching, developing, and commercializing therapeutics for life-threatening diseases. The company is best known for its antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and COVID-19. In recent years, Gilead has expanded its portfolio to include oncology and cell therapy treatments. The company operates globally, providing medicines to address unmet medical needs across various therapeutic areas.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
29,443,000
28,754,000
27,116,000
27,281,000
Cost of Sales
6,234,000
6,251,000
6,498,000
5,657,000
Gross Profit
23,209,000
22,503,000
20,618,000
21,624,000
Selling, General & Administrative Expenses
5,774,000
6,091,000
6,090,000
5,673,000
Research & Development Expenses
7,413,000
14,750,000
6,923,000
8,621,000
Operating Profit
10,022,000
1,662,000
7,605,000
7,330,000
Interest Expense
(1,024,000)
(977,000)
(944,000)
(935,000)
Non-Operating Income
798,000
6,000
198,000
(581,000)
Total Non-Operating Income
(226,000)
(971,000)
(746,000)
(1,516,000)
Income Before Provision for Income Taxes
9,796,000
690,000
6,859,000
5,814,000
Provision for Income Taxes
1,286,000
211,000
1,247,000
1,248,000
Consolidated Net Income
8,510,000
480,000
5,613,000
4,566,000
Net Income Attributable to Minority Interests and Other
—
—
(52,000)
(26,000)
Net Income Attributable to Common Shareholders
8,510,000
480,000
5,665,000
4,592,000
Basic EPS
6.84
0.38
4.54
3.66
Diluted EPS
6.78
0.38
4.50
3.64
Basic Weighted Average Shares Outstanding
1,244,000
1,247,000
1,248,000
1,255,000
Diluted Weighted Average Shares Outstanding
1,255,000
1,255,000
1,258,000
1,262,000
Shares Outstanding
1,241,000
1,246,000
1,246,000
1,247,000
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
7,564,000
9,991,000
6,085,000
5,412,000
Short-Term Investments
68,000
—
1,179,000
973,000
Total Cash and Cash Equivalents
7,632,000
9,991,000
7,264,000
6,385,000
Accounts Receivable
4,913,000
4,420,000
4,660,000
4,777,000
Total Trade Receivables
4,913,000
4,420,000
4,660,000
4,777,000
Inventories
1,774,000
1,710,000
1,787,000
1,507,000
Other Current Assets
4,024,000
3,052,000
2,374,000
1,774,000
Total Current Assets
18,342,000
19,173,000
16,085,000
14,443,000
Net Property, Plant & Equipment
5,606,000
5,414,000
5,317,000
5,475,000
Net Intangible Assets
16,978,000
19,948,000
26,454,000
28,894,000
Goodwill
8,314,000
8,314,000
8,314,000
8,314,000
Long-Term Investments
2,974,000
—
1,163,000
1,245,000
Other Long-Term Assets
6,809,000
6,147,000
4,792,000
4,800,000
Total Assets
59,023,000
58,995,000
62,125,000
63,171,000
Accounts Payable
715,000
833,000
550,000
905,000
Accrued Expenses
4,337,000
3,892,000
3,802,000
3,479,000
Current Portion of Long-Term Debt
2,807,000
1,815,000
1,798,000
2,273,000
Other Current Liabilities
3,953,000
5,464,000
5,130,000
4,580,000
Total Current Liabilities
11,813,000
12,004,000
11,280,000
11,237,000
Long-Term Debt
22,129,000
24,896,000
23,189,000
22,957,000
Other Long-Term Liabilities
2,463,000
2,849,000
4,907,000
7,768,000
Total Long-Term Liabilities
24,592,000
27,745,000
28,096,000
30,725,000
Total Liabilities
36,405,000
39,749,000
39,376,000
41,962,000
Common Stock
1,000
1,000
1,000
1,000
Additional Paid-in Capital
8,932,000
7,700,000
6,500,000
5,550,000
Accumulated Other Comprehensive Income
39,000
132,000
28,000
2,000
Retained Earnings
13,730,000
11,497,000
16,304,000
15,687,000
Total Common Shareholders' Equity
22,703,000
19,330,000
22,833,000
21,240,000
Minority Interests and Other
(84,000)
(84,000)
(84,000)
(31,000)
Total Shareholders' Equity
22,618,000
19,246,000
22,749,000
21,209,000
Total Liabilities and Shareholders' Equity
59,023,000
58,995,000
62,125,000
63,171,000
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
8,510,000
480,000
5,613,000
4,566,000
Depreciation & Amortization
2,760,000
2,767,000
2,693,000
2,103,000
Share-Based Compensation Expense
894,000
835,000
766,000
637,000
Other Adjustments
1,803,000
7,626,000
1,236,000
3,529,000
Changes in Trade Receivables
(367,000)
139,000
157,000
(406,000)
Changes in Inventories
(1,036,000)
(426,000)
(842,000)
(310,000)
Changes in Accounts Payable
(132,000)
290,000
(347,000)
226,000
Changes in Accrued Expenses
6,000
108,000
458,000
(775,000)
Changes in Income Taxes Payable
(2,108,000)
(732,000)
(1,768,000)
(364,000)
Changes in Other Operating Activities
(311,000)
(259,000)
39,000
(134,000)
Cash from Operating Activities
10,019,000
10,828,000
8,006,000
9,072,000
Capital Expenditure
(563,000)
(523,000)
(585,000)
(728,000)
Purchases of Investments
(4,072,000)
(736,000)
(2,372,000)
(1,942,000)
Proceeds from Sale of Investments
909,000
2,592,000
1,844,000
2,002,000
Payments for Business Acquisitions
(1,070,000)
(4,840,000)
(1,152,000)
(1,797,000)
Other Investing Activities
2,000
58,000
(1,000)
(1,000)
Cash from Investing Activities
(4,793,000)
(3,449,000)
(2,265,000)
(2,466,000)
Issuance of Long-Term Debt
—
3,464,000
1,980,000
—
Repayments of Long-Term Debt
(1,788,000)
(1,970,000)
(2,250,000)
(1,500,000)
Net Issuance / (Repayments) of Long-Term Debt
(1,788,000)
1,494,000
(270,000)
(1,500,000)
Issuance of Common Shares
408,000
422,000
232,000
309,000
Repurchases of Common Shares
(1,922,000)
(1,150,000)
(1,000,000)
(1,396,000)
Net Issuance / (Repurchases) of Common Shares
(1,514,000)
(728,000)
(768,000)
(1,087,000)
Common Share Dividends Paid
(4,003,000)
(3,918,000)
(3,809,000)
(3,709,000)
Other Financing Activities
(440,000)
(281,000)
(279,000)
(173,000)
Cash from Financing Activities
(7,745,000)
(3,433,000)
(5,125,000)
(6,469,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
92,000
(40,000)
57,000
(63,000)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash